Ranbaxy Begins Shipping Generic Lipitor From Indian Facility - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Ranbaxy Begins Shipping Generic Lipitor From Indian Facility

ePT--the Electronic Newsletter of Pharmaceutical Technology

Ranbaxy Laboratories has announced that beginning in March 2012, the first shipments of atorvastatin, the generic version of Pfizer’s Lipitor, had been sent to US markets from its new Mohali manufacturing facility located in Punjab, India.

Ranbaxy had received approval from FDA in November 2011, to produce atorvastatin at its Ohm Laboratory site in the US, but its Paonta Sahib, Batamandi, and Dewas, India facilities have been on FDA import alert since 2008. According to the company’s press release, Ranbaxy’s Mohali facility was granted approval from FDA in October 2011 to manufacture and market atorvastatin 10-, 20-, 40-, and 80-mg tablets. Ranbaxy expects the Mohali facility to manufacture oral solid products for export to US, EU, and other countries based on filings and after receiving the necessary approvals.

Arun Sawhney, CEO and managing director of Ranbaxy, said in the release, “The resumption of supplies from India into the US market, is a significant milestone for Ranbaxy. This is a testimony to our commitment to provide quality affordable medicines to the US healthcare system. Going forward, our Mohali facility will cater to the US and other geographies, improving access to medicines, in these regions.”


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here